// App-Quantinova.ai

304 : Rheumatoid Arthritis Patients Who Switched Treatment from Adalimumab to Upadacitinib Demonstrate a Robust Reduction of Inflammation-related Biomarkers: Proteomics Analysis from the SELECT-COMPARE Phase 3 Study

Researchers

Presenter

  • Iain B McInnes

Principal Investigators

  • Thierry Sornasse

  • Fang Cai

  • Heidi Camp

  • In-Ho Song

Medical Centers

  • AbbVie, Redwood City, CA

  • Abbvie, Winnetka, IL

  • Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

  • AbbVie, South San Francisco, CA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved